Put companies on watchlist
MediClin AG
ISIN: DE0006595101
WKN: 659510
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

MediClin AG · ISIN: DE0006595101 · EQS - Company News (52 News)
Country: Germany · Primary market: Germany · EQS NID: 1477595
02 November 2022 01:40PM

MediClin AG: Group sales and Group operating result above previous year − stable capacity utilization, energy costs weigh on result


EQS-News: MediClin AG / Key word(s): 9 Month figures
MediClin AG: Group sales and Group operating result above previous year − stable capacity utilization, energy costs weigh on result

02.11.2022 / 13:40 CET/CEST
The issuer is solely responsible for the content of this announcement.


Offenburg, November 2, 2022

Group sales and Group operating result above previous year − stable capacity utilization, energy costs weigh on result

 In the first nine months of 2022, MEDICLIN Aktiengesellschaft (MEDICLIN) achieved Group sales and a Group operating result above the respective comparative values of the prior-year period.

In the first nine months of 2022 Group sales of EUR 526.3 mill. were generated, which is EUR 28.2 mill. or 5.7 % more than in the first nine months of 2021. The Group operating result improved by EUR 8.7 mill. from EUR 1.4 mill. to EUR 10.1 mill. compared to the comparable prior-year period. The result was burdened by an increase in raw materials and consumables used by EUR 10.2 mill. or 11.5 %, referring in particular to higher energy costs which rose by EUR 7.1 mill. Staff costs increased by EUR 5.3 mill. or 1.7 %.

Sales increased in the segments and in the nursing care business area

In the post-acute segment sales rose by EUR 23.6 mill. or 7.9 %. The segment result improved, amounting to EUR 14.3 mill. compared to EUR 3.6 mill. in the prior-year period. The acute segment shows an increase in segment sales of EUR 3.4 mill. or 1.9 %. The segment result amounted to EUR −6.9 mill. (9M 2021: EUR −2.2 mill.). Sales of the nursing care business area improved by EUR 1.0 mill. up to EUR 13.9 mill. compared to the prior-year period.

High energy costs continue to weigh on the result

The high energy costs and rising general material costs continue to have a negative impact on earnings. "We use a variety of ways to save energy, but always under the prerequisite that the quality and hygiene requirements as well as the medical, therapeutic and nursing services are not impaired," said Dr. York Dhein, Member of the Management Board of MEDICLIN.

"As far as the delivery or allocation of gas is concerned, MEDICLIN belongs to the system-relevant industries whose supply is currently secured," adds the CEO, Dr. Joachim Raming.

Early renewal of leases for 20 clinic properties secures the future of MEDICLIN

On October 26, 2022, the leases for 20 clinics whose leases would have expired in 2027 were renewed. In this way, MEDICLIN ensures the operation of its clinics at the respective location. “The conditions of the new lease agreements apply from January 1, 2023 and will lead to a liquidity relief of around EUR 11.0 mill. p.a.,” explains Tino Fritz, CFO of MEDICLIN, the new contract terms.

Outlook – no change in guidance for financial year 2022

The development of capacity utilization so far in the 2022 financial year including October suggests stable use of medical and therapeutic services, but there is currently no noticeable increase in the use of services. However, the Management Board assumes that Group sales in the amount of the forecast corridor can be achieved. Group operating profit is expected to come out at the lower end of guidance.

The interim report as of September 30, 2022, is now available in German and English at www.mediclin.de.

 

About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510)

MEDICLIN includes 35 clinics, seven care facilities and eleven medical care centers. The Group has around 8,350 beds/care places and employs around 10,200 people. In a strong network, MEDICLIN offers the patient integrative care from the first visit to the doctor through the operation and subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDICLIN designs the care and support of people in need of care according to their individual needs and personal needs.

MEDICLIN ─ a company of the Asklepios Group.



02.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: MediClin AG
Okenstraße 27
77652 Offenburg
Germany
Phone: +49 (0)781 488-326
Fax: +49 (0)781 488-184
E-mail: alexandra.muehr@mediclin.de
Internet: www.mediclin.de
ISIN: DE0006595101
WKN: 659510
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1477595

 
End of News EQS News Service

1477595  02.11.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1477595&application_name=news&site_id=boersengefluester_html
Visual performance / price development - MediClin AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.